The FY23 Transformative Breast Cancer Consortium Award is designed to support collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applicants must bring together different perspectives to develop new paradigms that will solve fundamental yet overarching problems in breast cancer. This award requires a team-based approach by a consortium of exceptional researchers and advocates, whose collaborative efforts will make a transformative impact in breast cancer. The transformation intended by the consortium must be in people’s lives, and not in the healthcare or research system.
This funding opportunity is a separate mechanism from the Transformative Breast Cancer Consortium Development Award which is new for FY23 and is intended to provide successful applicants the time and resources needed to bring investigators and breast cancer advocates together to establish a consortium framework and conduct preliminary research to support application to a future, full Transformative Breast Cancer Consortium Award (pending availability of funds). For FY23, investigators may be named as Consortium Director on an application submitted to either (but not both) of these mechanisms. It is not necessary to receive a development award in order to apply for the current funding opportunity or anticipated full consortium awards in the future. Detailed information on the FY23 Transformative Breast Cancer Development Consortium Award is available under a separate program announcement (HT945-23-BCRP-TBCCDA).
For the FY23 Transformative Breast Cancer Consortium Award, the consortium should have at least four, but no more than five, project teams, each investigating different projects under a central hypothesis. No more than two project teams may be based at one institution. Each team’s work must be integrated within the consortium so that every component is working toward the consortium’s central hypothesis. Note: This award is not intended to replace, supplement, duplicate, or compete with other collaborative research efforts, such as the National Cancer Institute (NCI) Specialized Programs of Research Excellence (SPOREs), and it should not represent a collection of related Program Project grants or subprojects.
The proposed consortium’s overall work is expected to be innovative. In addition, the Transformative Breast Cancer Consortium Award will include funds for “seed projects” to pursue brand new, high-risk/high-reward concepts that arise from the work, during the award period.
Deadlines:
• Pre-Application Deadline: March 29, 2023
• Invitation to Submit an Application: May 2023
• Application Submission Deadline: June 28, 2023